In this randomised, controlled study in 14 low- and middle-income countries, individuals taking dolutegravir with darunavir/ritonavir for 48 weeks had a greater increase in systolic and diastolic blood pressure than individuals taking two nucleoside reverse transcriptase with darunavir/ritonavir. The difference remained significant after controlling for confounding factors including weight gain.

中文翻译：

---

抗逆转录病毒疗法与血压变化之间的关联：D2EFT 研究结果

在这项在 14 个低收入和中等收入国家进行的随机对照研究中，服用多替拉韦和达芦那韦/利托那韦 48 周的个体比服用两种核苷逆转录酶和达芦那韦/利托那韦的个体的收缩压和舒张压升高幅度更大。在控制了包括体重增加在内的混杂因素后，差异仍然显着。